Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
Net Loss Per Share (Details) - shares shares in Thousands	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Antidilutive securities excluded from the computation of diluted net loss per share
Total	22,790	21,153	22,790	21,153
Employee stock option
Antidilutive securities excluded from the computation of diluted net loss per share
Total	22,665	21,044	22,665	21,044
Purchase Plan
Antidilutive securities excluded from the computation of diluted net loss per share
Total	125	109	125	109